Table IV.

Comparison of responses to lenvatinib between the high-level and low-level CD8⁺ tumor infiltrating lymphocytes groups.

Response	All (n=15)%	High-level CD8+ TILs (n=5)%	Low-level CD8+ TILs (n=10)%	P-value
Overall Response				0.086
CR	1 (6.7)	0 (0)	1 (10)
PR	3 (20.0)	2 (40)	1 (10)
SD	6 (40)	0 (0)	6 (60)
PD	5 (33.3)	3 (60)	2 (20)
ORR (CR + PR)	4 (26.7)	2 (40)	2 (20)	0.417
DCR (CR + PR + SD)	10 (66.7)	2 (40)	8 (80)	0.121

TILs, tumor-infiltrating lymphocytes; CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease; ORR, objective response rate; DCR, disease control rate.